Payment overview · 2025
General Payments
$427.72
25 reported records · 10 companies
Healthcare provider profile · identity verified
Matthew Sampson, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAFFORD, AZ · NPI 1699881821
Verified facts
What the public records show
CMS Open Payments records show Matthew Sampson, MD received $427.72 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $117.82 | 27.6% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $97.08 | 22.7% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $49.38 | 11.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.68 | 8.3% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $29.29 | 6.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.17 | 6.8% | 2 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $19.19 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.14 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.75 | 3.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.22 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $427.72 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $100.42 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $81.32 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $49.38 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.17 | 2 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 291 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 277 | 66 |
| Lisinopril | Lisinopril | 277 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 276 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 255 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 244 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 226 | 49 |
| Furosemide | Furosemide | 223 | 57 |
| Omeprazole | Omeprazole | 209 | 49 |
| Losartan Potassium | Losartan Potassium | 196 | 53 |
| Metformin Hcl | Metformin Hcl | 189 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 178 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 157 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 29 |
| Simvastatin | Simvastatin | 125 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 111 | 25 |
| Glipizide | Glipizide | 99 | 25 |
| Ozempic | Semaglutide | 94 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 21 |
| Potassium Chloride | Potassium Chloride | 84 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 24 |
| Montelukast Sodium | Montelukast Sodium | 82 | 13 |
| Sertraline Hcl | Sertraline Hcl | 82 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 12 |
| Finasteride | Finasteride | 79 | 16 |
| Eliquis | Apixaban | 78 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | 18 |
| Carvedilol | Carvedilol | 70 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 20 |
| Tramadol Hcl | Tramadol Hcl | 56 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 20 |
| Spironolactone | Spironolactone | 52 | 14 |
| Trazodone Hcl | Trazodone Hcl | 52 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 47 | suppressed |
| Allopurinol | Allopurinol | 46 | suppressed |
| Prednisone | Prednisone | 46 | 38 |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 11 |
| Famotidine | Famotidine | 43 | 13 |
| Terazosin Hcl | Terazosin Hcl | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Meloxicam | Meloxicam | 40 | 15 |
| Progesterone | Progesterone, Micronized | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 29 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 27 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | 11 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 27 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 27 | 12 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 12 |
| Methylprednisolone | Methylprednisolone | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $427.72 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Doc Band, EVENITY, KISUNLA, Kerendia, NURTEC ODT, OTEZLA, REPATHA, Veozah, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error